Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This study has been completed.
Immunomedics, Inc.
Information provided by (Responsible Party):
Beth Christian, Ohio State University Comprehensive Cancer Center Identifier:
First received: October 2, 2009
Last updated: September 2, 2015
Last verified: September 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2015
  Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)